Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Hartmut Schmidt, John L. Berk et al.|The Lancet Neurology|2020Cited by 160
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With PolyneuropathyDavid Adams, Mónica Freitas, Jonas Wixner et al.|JAMA Neurology|2025Cited by 34
Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88L265P and CXCR4 mutations and underlying haemopathyAlexandre Guérémy, Émilien Delmont, José Boucraut et al.|Journal of Neurology|2023Cited by 5